1 Report Overview 1.1 Study Scope 1.2 Market Analysis by Type 1.2.1 Global Hospital-Treated Gram-Negative Infections Market Size Growth Rate by Type: 2017 VS 2021 VS 2028 1.2.2 Klebsiella 1.2.3 Acinetobacter 1.2.4 Coli 1.2.5 Cepacia 1.2.6 Pseudomonas 1.2.7 Serratia 1.2.8 Enterobacter 1.2.9 Others 1.3 Market by Application 1.3.1 Global Hospital-Treated Gram-Negative Infections Market Share by Application: 2017 VS 2021 VS 2028 1.3.2 Public Hospital 1.3.3 Private Hospital 1.4 Study Objectives 1.5 Years Considered 2 Global Growth Trends 2.1 Global Hospital-Treated Gram-Negative Infections Market Perspective (2017-2028) 2.2 Hospital-Treated Gram-Negative Infections Growth Trends by Region 2.2.1 Hospital-Treated Gram-Negative Infections Market Size by Region: 2017 VS 2021 VS 2028 2.2.2 Hospital-Treated Gram-Negative Infections Historic Market Size by Region (2017-2022) 2.2.3 Hospital-Treated Gram-Negative Infections Forecasted Market Size by Region (2023-2028) 2.3 Hospital-Treated Gram-Negative Infections Market Dynamics 2.3.1 Hospital-Treated Gram-Negative Infections Industry Trends 2.3.2 Hospital-Treated Gram-Negative Infections Market Drivers 2.3.3 Hospital-Treated Gram-Negative Infections Market Challenges 2.3.4 Hospital-Treated Gram-Negative Infections Market Restraints 3 Competition Landscape by Key Players 3.1 Global Top Hospital-Treated Gram-Negative Infections Players by Revenue 3.1.1 Global Top Hospital-Treated Gram-Negative Infections Players by Revenue (2017-2022) 3.1.2 Global Hospital-Treated Gram-Negative Infections Revenue Market Share by Players (2017-2022) 3.2 Global Hospital-Treated Gram-Negative Infections Market Share by Company Type (Tier 1, Tier 2, and Tier 3) 3.3 Players Covered: Ranking by Hospital-Treated Gram-Negative Infections Revenue 3.4 Global Hospital-Treated Gram-Negative Infections Market Concentration Ratio 3.4.1 Global Hospital-Treated Gram-Negative Infections Market Concentration Ratio (CR5 and HHI) 3.4.2 Global Top 10 and Top 5 Companies by Hospital-Treated Gram-Negative Infections Revenue in 2021 3.5 Hospital-Treated Gram-Negative Infections Key Players Head office and Area Served 3.6 Key Players Hospital-Treated Gram-Negative Infections Product Solution and Service 3.7 Date of Enter into Hospital-Treated Gram-Negative Infections Market 3.8 Mergers & Acquisitions, Expansion Plans 4 Hospital-Treated Gram-Negative Infections Breakdown Data by Type 4.1 Global Hospital-Treated Gram-Negative Infections Historic Market Size by Type (2017-2022) 4.2 Global Hospital-Treated Gram-Negative Infections Forecasted Market Size by Type (2023-2028) 5 Hospital-Treated Gram-Negative Infections Breakdown Data by Application 5.1 Global Hospital-Treated Gram-Negative Infections Historic Market Size by Application (2017-2022) 5.2 Global Hospital-Treated Gram-Negative Infections Forecasted Market Size by Application (2023-2028) 6 North America 6.1 North America Hospital-Treated Gram-Negative Infections Market Size (2017-2028) 6.2 North America Hospital-Treated Gram-Negative Infections Market Size by Country (2017-2022) 6.3 North America Hospital-Treated Gram-Negative Infections Market Size by Country (2023-2028) 6.4 United States 6.5 Canada 7 Europe 7.1 Europe Hospital-Treated Gram-Negative Infections Market Size (2017-2028) 7.2 Europe Hospital-Treated Gram-Negative Infections Market Size by Country (2017-2022) 7.3 Europe Hospital-Treated Gram-Negative Infections Market Size by Country (2023-2028) 7.4 Germany 7.5 France 7.6 U.K. 7.7 Italy 7.8 Russia 7.9 Nordic Countries 8 Asia-Pacific 8.1 Asia-Pacific Hospital-Treated Gram-Negative Infections Market Size (2017-2028) 8.2 Asia-Pacific Hospital-Treated Gram-Negative Infections Market Size by Country (2017-2022) 8.3 Asia-Pacific Hospital-Treated Gram-Negative Infections Market Size by Country (2023-2028) 8.4 China 8.5 Japan 8.6 South Korea 8.7 Southeast Asia 8.8 India 8.9 Australia 9 Latin America 9.1 Latin America Hospital-Treated Gram-Negative Infections Market Size (2017-2028) 9.2 Latin America Hospital-Treated Gram-Negative Infections Market Size by Country (2017-2022) 9.3 Latin America Hospital-Treated Gram-Negative Infections Market Size by Country (2023-2028) 9.4 Mexico 9.5 Brazil 10 Middle East & Africa 10.1 Middle East & Africa Hospital-Treated Gram-Negative Infections Market Size (2017-2028) 10.2 Middle East & Africa Hospital-Treated Gram-Negative Infections Market Size by Country (2017-2022) 10.3 Middle East & Africa Hospital-Treated Gram-Negative Infections Market Size by Country (2023-2028) 10.4 Turkey 10.5 Saudi Arabia 10.6 UAE 11 Key Players Profiles 11.1 Merck 11.1.1 Merck Company Detail 11.1.2 Merck Business Overview 11.1.3 Merck Hospital-Treated Gram-Negative Infections Introduction 11.1.4 Merck Revenue in Hospital-Treated Gram-Negative Infections Business (2017-2022) 11.1.5 Merck Recent Development 11.2 Pfizer 11.2.1 Pfizer Company Detail 11.2.2 Pfizer Business Overview 11.2.3 Pfizer Hospital-Treated Gram-Negative Infections Introduction 11.2.4 Pfizer Revenue in Hospital-Treated Gram-Negative Infections Business (2017-2022) 11.2.5 Pfizer Recent Development 11.3 AstraZeneca 11.3.1 AstraZeneca Company Detail 11.3.2 AstraZeneca Business Overview 11.3.3 AstraZeneca Hospital-Treated Gram-Negative Infections Introduction 11.3.4 AstraZeneca Revenue in Hospital-Treated Gram-Negative Infections Business (2017-2022) 11.3.5 AstraZeneca Recent Development 11.4 Abbott 11.4.1 Abbott Company Detail 11.4.2 Abbott Business Overview 11.4.3 Abbott Hospital-Treated Gram-Negative Infections Introduction 11.4.4 Abbott Revenue in Hospital-Treated Gram-Negative Infections Business (2017-2022) 11.4.5 Abbott Recent Development 11.5 Lupin Pharmaceuticals 11.5.1 Lupin Pharmaceuticals Company Detail 11.5.2 Lupin Pharmaceuticals Business Overview 11.5.3 Lupin Pharmaceuticals Hospital-Treated Gram-Negative Infections Introduction 11.5.4 Lupin Pharmaceuticals Revenue in Hospital-Treated Gram-Negative Infections Business (2017-2022) 11.5.5 Lupin Pharmaceuticals Recent Development 11.6 Istituto lusofarmaco d’italia 11.6.1 Istituto lusofarmaco d’italia Company Detail 11.6.2 Istituto lusofarmaco d’italia Business Overview 11.6.3 Istituto lusofarmaco d’italia Hospital-Treated Gram-Negative Infections Introduction 11.6.4 Istituto lusofarmaco d’italia Revenue in Hospital-Treated Gram-Negative Infections Business (2017-2022) 11.6.5 Istituto lusofarmaco d’italia Recent Development 11.7 Adelco S.A 11.7.1 Adelco S.A Company Detail 11.7.2 Adelco S.A Business Overview 11.7.3 Adelco S.A Hospital-Treated Gram-Negative Infections Introduction 11.7.4 Adelco S.A Revenue in Hospital-Treated Gram-Negative Infections Business (2017-2022) 11.7.5 Adelco S.A Recent Development 11.8 Zhejiang yuntao biotechnology co., Ltd 11.8.1 Zhejiang yuntao biotechnology co., Ltd Company Detail 11.8.2 Zhejiang yuntao biotechnology co., Ltd Business Overview 11.8.3 Zhejiang yuntao biotechnology co., Ltd Hospital-Treated Gram-Negative Infections Introduction 11.8.4 Zhejiang yuntao biotechnology co., Ltd Revenue in Hospital-Treated Gram-Negative Infections Business (2017-2022) 11.8.5 Zhejiang yuntao biotechnology co., Ltd Recent Development 11.9 Alcon Laboratories 11.9.1 Alcon Laboratories Company Detail 11.9.2 Alcon Laboratories Business Overview 11.9.3 Alcon Laboratories Hospital-Treated Gram-Negative Infections Introduction 11.9.4 Alcon Laboratories Revenue in Hospital-Treated Gram-Negative Infections Business (2017-2022) 11.9.5 Alcon Laboratories Recent Development 12 Analyst's Viewpoints/Conclusions 13 Appendix 13.1 Research Methodology 13.1.1 Methodology/Research Approach 13.1.2 Data Source 13.2 Disclaimer 13.3 Author Details

List of Tables Table 1. Global Hospital-Treated Gram-Negative Infections Market Size Growth Rate by Type (US$ Million): 2017 VS 2021 VS 2028 Table 2. Key Players of Klebsiella Table 3. Key Players of Acinetobacter Table 4. Key Players of Coli Table 5. Key Players of Cepacia Table 6. Key Players of Pseudomonas Table 7. Key Players of Serratia Table 8. Key Players of Enterobacter Table 9. Key Players of Others Table 10. Global Hospital-Treated Gram-Negative Infections Market Size Growth by Application (US$ Million): 2017 VS 2021 VS 2028 Table 11. Global Hospital-Treated Gram-Negative Infections Market Size by Region (US$ Million): 2017 VS 2021 VS 2028 Table 12. Global Hospital-Treated Gram-Negative Infections Market Size by Region (2017-2022) & (US$ Million) Table 13. Global Hospital-Treated Gram-Negative Infections Market Share by Region (2017-2022) Table 14. Global Hospital-Treated Gram-Negative Infections Forecasted Market Size by Region (2023-2028) & (US$ Million) Table 15. Global Hospital-Treated Gram-Negative Infections Market Share by Region (2023-2028) Table 16. Hospital-Treated Gram-Negative Infections Market Trends Table 17. Hospital-Treated Gram-Negative Infections Market Drivers Table 18. Hospital-Treated Gram-Negative Infections Market Challenges Table 19. Hospital-Treated Gram-Negative Infections Market Restraints Table 20. Global Hospital-Treated Gram-Negative Infections Revenue by Players (2017-2022) & (US$ Million) Table 21. Global Hospital-Treated Gram-Negative Infections Market Share by Players (2017-2022) Table 22. Global Top Hospital-Treated Gram-Negative Infections Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hospital-Treated Gram-Negative Infections as of 2021) Table 23. Ranking of Global Top Hospital-Treated Gram-Negative Infections Companies by Revenue (US$ Million) in 2021 Table 24. Global 5 Largest Players Market Share by Hospital-Treated Gram-Negative Infections Revenue (CR5 and HHI) & (2017-2022) Table 25. Key Players Headquarters and Area Served Table 26. Key Players Hospital-Treated Gram-Negative Infections Product Solution and Service Table 27. Date of Enter into Hospital-Treated Gram-Negative Infections Market Table 28. Mergers & Acquisitions, Expansion Plans Table 29. Global Hospital-Treated Gram-Negative Infections Market Size by Type (2017-2022) & (US$ Million) Table 30. Global Hospital-Treated Gram-Negative Infections Revenue Market Share by Type (2017-2022) Table 31. Global Hospital-Treated Gram-Negative Infections Forecasted Market Size by Type (2023-2028) & (US$ Million) Table 32. Global Hospital-Treated Gram-Negative Infections Revenue Market Share by Type (2023-2028) Table 33. Global Hospital-Treated Gram-Negative Infections Market Size by Application (2017-2022) & (US$ Million) Table 34. Global Hospital-Treated Gram-Negative Infections Revenue Market Share by Application (2017-2022) Table 35. Global Hospital-Treated Gram-Negative Infections Forecasted Market Size by Application (2023-2028) & (US$ Million) Table 36. Global Hospital-Treated Gram-Negative Infections Revenue Market Share by Application (2023-2028) Table 37. North America Hospital-Treated Gram-Negative Infections Market Size by Country (2017-2022) & (US$ Million) Table 38. North America Hospital-Treated Gram-Negative Infections Market Size by Country (2023-2028) & (US$ Million) Table 39. Europe Hospital-Treated Gram-Negative Infections Market Size by Country (2017-2022) & (US$ Million) Table 40. Europe Hospital-Treated Gram-Negative Infections Market Size by Country (2023-2028) & (US$ Million) Table 41. Asia-Pacific Hospital-Treated Gram-Negative Infections Market Size by Region (2017-2022) & (US$ Million) Table 42. Asia-Pacific Hospital-Treated Gram-Negative Infections Market Size by Region (2023-2028) & (US$ Million) Table 43. Latin America Hospital-Treated Gram-Negative Infections Market Size by Country (2017-2022) & (US$ Million) Table 44. Latin America Hospital-Treated Gram-Negative Infections Market Size by Country (2023-2028) & (US$ Million) Table 45. Middle East & Africa Hospital-Treated Gram-Negative Infections Market Size by Country (2017-2022) & (US$ Million) Table 46. Middle East & Africa Hospital-Treated Gram-Negative Infections Market Size by Country (2023-2028) & (US$ Million) Table 47. Merck Company Detail Table 48. Merck Business Overview Table 49. Merck Hospital-Treated Gram-Negative Infections Product Table 50. Merck Revenue in Hospital-Treated Gram-Negative Infections Business (2017-2022) & (US$ Million) Table 51. Merck Recent Development Table 52. Pfizer Company Detail Table 53. Pfizer Business Overview Table 54. Pfizer Hospital-Treated Gram-Negative Infections Product Table 55. Pfizer Revenue in Hospital-Treated Gram-Negative Infections Business (2017-2022) & (US$ Million) Table 56. Pfizer Recent Development Table 57. AstraZeneca Company Detail Table 58. AstraZeneca Business Overview Table 59. AstraZeneca Hospital-Treated Gram-Negative Infections Product Table 60. AstraZeneca Revenue in Hospital-Treated Gram-Negative Infections Business (2017-2022) & (US$ Million) Table 61. AstraZeneca Recent Development Table 62. Abbott Company Detail Table 63. Abbott Business Overview Table 64. Abbott Hospital-Treated Gram-Negative Infections Product Table 65. Abbott Revenue in Hospital-Treated Gram-Negative Infections Business (2017-2022) & (US$ Million) Table 66. Abbott Recent Development Table 67. Lupin Pharmaceuticals Company Detail Table 68. Lupin Pharmaceuticals Business Overview Table 69. Lupin Pharmaceuticals Hospital-Treated Gram-Negative Infections Product Table 70. Lupin Pharmaceuticals Revenue in Hospital-Treated Gram-Negative Infections Business (2017-2022) & (US$ Million) Table 71. Lupin Pharmaceuticals Recent Development Table 72. Istituto lusofarmaco d’italia Company Detail Table 73. Istituto lusofarmaco d’italia Business Overview Table 74. Istituto lusofarmaco d’italia Hospital-Treated Gram-Negative Infections Product Table 75. Istituto lusofarmaco d’italia Revenue in Hospital-Treated Gram-Negative Infections Business (2017-2022) & (US$ Million) Table 76. Istituto lusofarmaco d’italia Recent Development Table 77. Adelco S.A Company Detail Table 78. Adelco S.A Business Overview Table 79. Adelco S.A Hospital-Treated Gram-Negative Infections Product Table 80. Adelco S.A Revenue in Hospital-Treated Gram-Negative Infections Business (2017-2022) & (US$ Million) Table 81. Adelco S.A Recent Development Table 82. Zhejiang yuntao biotechnology co., Ltd Company Detail Table 83. Zhejiang yuntao biotechnology co., Ltd Business Overview Table 84. Zhejiang yuntao biotechnology co., Ltd Hospital-Treated Gram-Negative Infections Product Table 85. Zhejiang yuntao biotechnology co., Ltd Revenue in Hospital-Treated Gram-Negative Infections Business (2017-2022) & (US$ Million) Table 86. Zhejiang yuntao biotechnology co., Ltd Recent Development Table 87. Alcon Laboratories Company Detail Table 88. Alcon Laboratories Business Overview Table 89. Alcon Laboratories Hospital-Treated Gram-Negative Infections Product Table 90. Alcon Laboratories Revenue in Hospital-Treated Gram-Negative Infections Business (2017-2022) & (US$ Million) Table 91. Alcon Laboratories Recent Development Table 92. Research Programs/Design for This Report Table 93. Key Data Information from Secondary Sources Table 94. Key Data Information from Primary Sources List of Figures Figure 1. Global Hospital-Treated Gram-Negative Infections Market Share by Type: 2021 VS 2028 Figure 2. Klebsiella Features Figure 3. Acinetobacter Features Figure 4. Coli Features Figure 5. Cepacia Features Figure 6. Pseudomonas Features Figure 7. Serratia Features Figure 8. Enterobacter Features Figure 9. Others Features Figure 10. Global Hospital-Treated Gram-Negative Infections Market Share by Application in 2021 & 2028 Figure 11. Public Hospital Case Studies Figure 12. Private Hospital Case Studies Figure 13. Hospital-Treated Gram-Negative Infections Report Years Considered Figure 14. Global Hospital-Treated Gram-Negative Infections Market Size (US$ Million), Year-over-Year: 2017-2028 Figure 15. Global Hospital-Treated Gram-Negative Infections Market Size, (US$ Million), 2017 VS 2021 VS 2028 Figure 16. Global Hospital-Treated Gram-Negative Infections Market Share by Region: 2021 VS 2028 Figure 17. Global Hospital-Treated Gram-Negative Infections Market Share by Players in 2021 Figure 18. Global Top Hospital-Treated Gram-Negative Infections Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hospital-Treated Gram-Negative Infections as of 2021) Figure 19. The Top 10 and 5 Players Market Share by Hospital-Treated Gram-Negative Infections Revenue in 2021 Figure 20. North America Hospital-Treated Gram-Negative Infections Market Size YoY Growth (2017-2028) & (US$ Million) Figure 21. North America Hospital-Treated Gram-Negative Infections Market Share by Country (2017-2028) Figure 22. United States Hospital-Treated Gram-Negative Infections Market Size YoY Growth (2017-2028) & (US$ Million) Figure 23. Canada Hospital-Treated Gram-Negative Infections Market Size YoY Growth (2017-2028) & (US$ Million) Figure 24. Europe Hospital-Treated Gram-Negative Infections Market Size YoY Growth (2017-2028) & (US$ Million) Figure 25. Europe Hospital-Treated Gram-Negative Infections Market Share by Country (2017-2028) Figure 26. Germany Hospital-Treated Gram-Negative Infections Market Size YoY Growth (2017-2028) & (US$ Million) Figure 27. France Hospital-Treated Gram-Negative Infections Market Size YoY Growth (2017-2028) & (US$ Million) Figure 28. U.K. Hospital-Treated Gram-Negative Infections Market Size YoY Growth (2017-2028) & (US$ Million) Figure 29. Italy Hospital-Treated Gram-Negative Infections Market Size YoY Growth (2017-2028) & (US$ Million) Figure 30. Russia Hospital-Treated Gram-Negative Infections Market Size YoY Growth (2017-2028) & (US$ Million) Figure 31. Nordic Countries Hospital-Treated Gram-Negative Infections Market Size YoY Growth (2017-2028) & (US$ Million) Figure 32. Asia-Pacific Hospital-Treated Gram-Negative Infections Market Size YoY Growth (2017-2028) & (US$ Million) Figure 33. Asia-Pacific Hospital-Treated Gram-Negative Infections Market Share by Region (2017-2028) Figure 34. China Hospital-Treated Gram-Negative Infections Market Size YoY Growth (2017-2028) & (US$ Million) Figure 35. Japan Hospital-Treated Gram-Negative Infections Market Size YoY Growth (2017-2028) & (US$ Million) Figure 36. South Korea Hospital-Treated Gram-Negative Infections Market Size YoY Growth (2017-2028) & (US$ Million) Figure 37. Southeast Asia Hospital-Treated Gram-Negative Infections Market Size YoY Growth (2017-2028) & (US$ Million) Figure 38. India Hospital-Treated Gram-Negative Infections Market Size YoY Growth (2017-2028) & (US$ Million) Figure 39. Australia Hospital-Treated Gram-Negative Infections Market Size YoY Growth (2017-2028) & (US$ Million) Figure 40. Latin America Hospital-Treated Gram-Negative Infections Market Size YoY Growth (2017-2028) & (US$ Million) Figure 41. Latin America Hospital-Treated Gram-Negative Infections Market Share by Country (2017-2028) Figure 42. Mexico Hospital-Treated Gram-Negative Infections Market Size YoY Growth (2017-2028) & (US$ Million) Figure 43. Brazil Hospital-Treated Gram-Negative Infections Market Size YoY Growth (2017-2028) & (US$ Million) Figure 44. Middle East & Africa Hospital-Treated Gram-Negative Infections Market Size YoY Growth (2017-2028) & (US$ Million) Figure 45. Middle East & Africa Hospital-Treated Gram-Negative Infections Market Share by Country (2017-2028) Figure 46. Turkey Hospital-Treated Gram-Negative Infections Market Size YoY Growth (2017-2028) & (US$ Million) Figure 47. Saudi Arabia Hospital-Treated Gram-Negative Infections Market Size YoY Growth (2017-2028) & (US$ Million) Figure 48. Merck Revenue Growth Rate in Hospital-Treated Gram-Negative Infections Business (2017-2022) Figure 49. Pfizer Revenue Growth Rate in Hospital-Treated Gram-Negative Infections Business (2017-2022) Figure 50. AstraZeneca Revenue Growth Rate in Hospital-Treated Gram-Negative Infections Business (2017-2022) Figure 51. Abbott Revenue Growth Rate in Hospital-Treated Gram-Negative Infections Business (2017-2022) Figure 52. Lupin Pharmaceuticals Revenue Growth Rate in Hospital-Treated Gram-Negative Infections Business (2017-2022) Figure 53. Istituto lusofarmaco d’italia Revenue Growth Rate in Hospital-Treated Gram-Negative Infections Business (2017-2022) Figure 54. Adelco S.A Revenue Growth Rate in Hospital-Treated Gram-Negative Infections Business (2017-2022) Figure 55. Zhejiang yuntao biotechnology co., Ltd Revenue Growth Rate in Hospital-Treated Gram-Negative Infections Business (2017-2022) Figure 56. Alcon Laboratories Revenue Growth Rate in Hospital-Treated Gram-Negative Infections Business (2017-2022) Figure 57. Bottom-up and Top-down Approaches for This Report Figure 58. Data Triangulation Figure 59. Key Executives Interviewed

Merck Pfizer AstraZeneca Abbott Lupin Pharmaceuticals Istituto lusofarmaco d’italia Adelco S.A Zhejiang yuntao biotechnology co., Ltd Alcon Laboratories